AVISIT,AVALC,0,54,81,p
,Assessment,Placebo\line (N=79),Xanomeline\line Low Dose\line (N=81),Xanomeline\line High Dose\line (N=74),p-value\line [1]
Week 8,n,77       ,81       ,73       ,0.2727
,Marked improvement, 0       , 0       , 0       ,
,Moderate improvement, 1 (  1%), 2 (  2%), 1 (  1%),
,Minimal improvement,19 ( 25%),16 ( 20%),13 ( 18%),
,No Change,45 ( 58%),48 ( 59%),38 ( 52%),
,Minimal worsening,10 ( 13%),14 ( 17%),20 ( 27%),
,Moderate worsening, 2 (  3%), 1 (  1%), 1 (  1%),
,Marked worsening, 0       , 0       , 0       ,
,,,,,
Week 16,n,79       ,81       ,74       ,0.4003
,Marked improvement, 0       , 0       , 0       ,
,Moderate improvement, 0       , 3 (  4%), 2 (  3%),
,Minimal improvement,12 ( 15%),12 ( 15%),13 ( 18%),
,No Change,41 ( 52%),46 ( 57%),39 ( 53%),
,Minimal worsening,25 ( 32%),19 ( 23%),20 ( 27%),
,Moderate worsening, 1 (  1%), 1 (  1%), 0       ,
,Marked worsening, 0       , 0       , 0       ,
,,,,,
Week 24,n,79       ,81       ,74       ,0.6180
,Marked improvement, 0       , 0       , 0       ,
,Moderate improvement, 1 (  1%), 1 (  1%), 0       ,
,Minimal improvement, 9 ( 11%),14 ( 17%),11 ( 15%),
,No Change,38 ( 48%),37 ( 46%),33 ( 45%),
,Minimal worsening,28 ( 35%),27 ( 33%),25 ( 34%),
,Moderate worsening, 3 (  4%), 2 (  2%), 5 (  7%),
,Marked worsening, 0       , 0       , 0       ,
,,,,,
